Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.29 USD | +0.78% | +2.36% | +11.11% |
05-13 | HC Wainwright Adjusts Price Target on Clearside Biomedical to $5 From $6, Keeps Buy Rating | MT |
05-09 | Transcript : Clearside Biomedical, Inc., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.11% | 95.66M | |
+7.76% | 111B | |
+11.19% | 106B | |
-12.23% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-9.04% | 16.81B | |
+38.48% | 12.54B | |
-24.55% | 8.09B |
- Stock Market
- Equities
- CLSD Stock
- News Clearside Biomedical, Inc.
- Wedbush Adds Outperform-Rated Clearside Biomedical to Best Ideas List, Citing 'Potentially Transformative Dual Approach' for wAMD Treatment, Adjusts PT to $9 From $19 on Peak Sale Estimates